Health

First Major Clinical Trials Show Magic Mushrooms Heal Mental Illness like a ‘Surgical Intervention’

Clinical trials demonstrate the effects of magic mushrooms on the brain.

The benefits of magic mushrooms on the brain have been documented for the first time in clinical trials.

The effect of psychedelics on the brain have long been documented, but never in such a scientific way. The overwhelming experience people have from taking them recreationally is generally positive but now the great scientific benefits they have on the brain has been revealed.

Psilocybins, the reactive compound found in magic mushrooms are known to have a overwhelmingly positive effect on people suffering with severe mental problems, such as PTSD or the stress associated with having a terminal illness.

William Richards at Johns Hopkins University is behind the research, who has been treating patients with psilocybin for 15 years.

His most recent studies have been published in the Journal of Psychopharmacology with the titles:

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial

And

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial

The results of psilocybins on the brain were found to be incredibly beneficial for people suffering from anxiety and depression, and life threatening cancer.

The stigma surround drugs that are still to be granted the praise of being struck off the ‘illegal’ list still suffer from many stigma and negative associations. People are more than happy to take numerous pills a day that the doctor has given them, but ones still classified as illegal are seen as risky.

This study will hopefully change the attitudes people have to psychedelics, the benefits of these drugs cannot be ignored much longer.

The study noted:

“Prior to the crossover, psilocybin produced immediate, substantial, and sustained improvements in anxiety and depression and led to decreases in cancer-related demoralization and hopelessness, improved spiritual wellbeing, and increased quality of life.

At the 6.5-month follow-up, psilocybin was associated with enduring anxiolytic and anti-depressant effects (approximately 60–80% of participants continued with clinically significant reductions in depression or anxiety), sustained benefits in existential distress and quality of life, as well as improved attitudes towards death. The psilocybin-induced mystical experience mediated the therapeutic effect of psilocybin on anxiety and depression.”

And from the summary:

“…a single dose of psilocybin produced substantial and enduring decreases in depressed mood and anxiety along with increases in quality of life and decreases in death anxiety in patients with a life-threatening cancer diagnosis. Ratings by patients themselves, clinicians, and community observers suggested these effects endured at least 6 months. The overall rate of clinical response at 6 months on clinician-rated depression and anxiety was 78% and 83%, respectively.”

Share this post:

Most Popular

To Top